KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Assets (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Current Assets for 9 consecutive years, with $404.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 4.18% year-over-year to $404.3 million, compared with a TTM value of $404.3 million through Dec 2025, down 4.18%, and an annual FY2025 reading of $404.3 million, down 4.18% over the prior year.
  • Current Assets was $404.3 million for Q4 2025 at Biocryst Pharmaceuticals, up from $398.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $511.1 million in Q2 2023 and bottomed at $363.5 million in Q2 2024.
  • Average Current Assets over 3 years is $443.0 million, with a median of $427.1 million recorded in 2024.
  • The sharpest move saw Current Assets dropped 28.88% in 2024, then increased 9.63% in 2025.
  • Year by year, Current Assets stood at $496.0 million in 2023, then decreased by 14.92% to $422.0 million in 2024, then decreased by 4.18% to $404.3 million in 2025.
  • Business Quant data shows Current Assets for BCRX at $404.3 million in Q4 2025, $398.5 million in Q2 2025, and $410.0 million in Q1 2025.